Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

Procanbid (procainamide hydrochloride extended-release tablets)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved January 1996

Specific Treatments:

ventricular arrhythmias

General Information

Procanbid has been approved for the treatment of ventricular arrhythmias. While other procainamides are designed for dosage every six hours, patients taking Procanbid can achieve therapeutic blood levels with dosing every 12 hours.

Procanbid is available in 500 mg and 1000 mg tablets.

Additional Information

Ventricular arrhythmia often arises from atypical electrical activity in the ventricles that causes the heart to beat abnormally and affects approximately one million people annually in the United States. The condition is responsible for more than 80 percent of sudden cardiac deaths (SCD). In the United States, approximately 400,000 SCDs occur each year.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation